GTC Biotherapeutics (fka GTCB)

[ThomasS]

Thanks. Follow-on: I do not recall what shareholder rights provisions are currently in-place. If a potential acquirer were to materialize, what processes would come into play? (Perhaps another entry for the read-me-first?)

(This mates with my answer to the survey re "future GTCB valuation," where I voted my opinion that GTCB would not exist beyond 2008.)

EDIT: "Having said that, I think it's very clear from everything that I've said that we believe that we've got multiple opportunities from a partnering collaboration perspective and we have significantly reinforced our capabilities from a business development perspective in order to be able to address that opportunity."

"There are not many companies out there who have the range of opportunities that we have nor the type of business model that we have. And that's something which we really want to be able to leverage in these number of different directions; so the answer to your question is, yes, we are engaged in a number of discussions at this moment. We expect to expand the number of discussions. When they will come to fruition is a little difficult to predict but it's clearly something which we are actively engaged in at this moment and we hope to have news during the course of the year."


IF a larger entity were engaged in serious partnering negotiations for a large drug, it would make little sense to commit to prospective milestones and royalties on such drug, given that GTC (and it's entire portfolio/patents) could be had for a song today .

(An acquirer could have GTC for less than the total value of future ATRYN sales across all indications.)